Gregor Blank

Title: Gregor Blank: Innovator in Immunosuppressive Therapy

Introduction

Gregor Blank is a notable inventor based in Tübingen, Germany. He has made significant contributions to the field of immunosuppressive therapy through his innovative research and development of specialized polypeptides. His work focuses on enhancing therapeutic methods that target the alpha beta T cell receptor.

Latest Patents

Gregor Blank holds a patent titled "Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptide." This patent describes improved methods for utilizing a humanized binding polypeptide that is specific for the alpha beta T cell receptor. The disclosure emphasizes the use of a humanized anti-αβ-TCR antibody, derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. The novel methods include repetitive administration of humanized monoclonal antibodies and fragments to effectively reduce αβ T cells in subjects.

Career Highlights

Throughout his career, Gregor Blank has worked with prominent organizations, including Genzyme Corporation and Eberhard Karls Universität Tübingen. His experience in these institutions has allowed him to advance his research and contribute to the scientific community significantly.

Collaborations

Gregor has collaborated with esteemed colleagues such as Rupert Handgretinger and Karin Schilbach. Their joint efforts have furthered the understanding and application of immunosuppressive therapies.

Conclusion

Gregor Blank's innovative work in immunosuppressive therapy showcases his dedication to advancing medical science. His patent and collaborations highlight the importance of research in developing effective treatments for patients.